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1. Introduction
Many functional proteins act as oligomers. Oligomerization is a well-controlled and regulated
process. Those proteins cannot adopt their physiological functions without oligomerization,
while the protein misfolding and subsequent unphysiological oligomerization influence the
primary protein functions and produce a “gain in toxic function” as the prefibrillar oligomers
are toxic for the cells. Misfolding, oligomerization and aggregation are the reasons for the so
called conformational diseases. Several of them are neurodegenerative, but some also affect
other vital organs. The accumulation of intracellular protein aggregates (various inclusions)
and of extracellular protein deposits cause severe cellular degeneration, such as neurodegen‐
eration of affected neurons. Different proteins form rather similar but not identical fibrillar
structures, all showing cross-β-structure, where continuous β-sheets run perpendicular to the
long axis of the fibrils.
Neurodegenerative diseases like Alzheimer’s disease, Parkinson’s disease, Huntington’s
disease, prion diseases and many others have in common protein aggregation to amyloid
fibrils. Type II diabetes is also an amyloid disease although it is not neurodegenerative.
Nowadays it is believed that ordered prefibrillar oligomers or protofibrils may be responsible
for cell death and that mature fibrils may even be neuroprotective. Most amyloid prone
proteins form different oligomers in the lag phase of the amyloid fibril formation. Conforma‐
tional diseases (Table 1) are difficult to diagnose in the early stage, because they are usually a-
symptomatic during their development. Even when they can be diagnosed in the early stage
there is an ethical reason for avoiding diagnosis (i.e. to hesitate letting know the patient or the
relatives), because there are still no therapies which would slow down or even stop the
progression of this type of diseases. Many different proteins are being studied in order to
understand the common molecular mechanism of the conformational disease and to develop
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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appropriate treatments. Studies use in vitro (different spectroscopic methods), ex vivo (different
cell cultures) and in vivo (mouse models) systems to clarify the changes of the protein confor‐
mation and the down-stream effects during the whole process.
Conformational diseases ( organ/systemic) ) Protein
Alzheimer’s disease, Down’s syndrome (Trisomy 21), Hereditary cerebral
angiopathy (Dutch) Amyloid precursor protein (Aβ 1-42)
Kuru, Gerstmann-Straussler-Scheinker Syndrome (GSS), Creutzfeld-Jacob
disease, Scrapie (sheep), Bovine spongiform encephalopathy (“mad cow”) Prion protein
Type II diabetes mellitus (adult onset) Islet amyloid polypeptide (amylin)
Dialysis-associated amyloidosis β2-microglobulin
Senile cardiac amyloidosis Atrial natriuretic factor
Familial amyloid polyneuropathy Transthyretin
Reactive amyloidosis familial Mediterranean fever Serum amyloid A
Familial amyloid polyneuropathy (Finnish) Gelsolin
Macroglobulinemia Gamma-1 heavy chain
Primary systemic amyloidosis Ig-lambda, Ig-kappa
Familial polyneuropathy – Iowa (Irish) Apolipoprotein A1
Hereditary cerebral myopathy – Iceland Cystatin C
Nonneuropathic hereditary amyloid with renal disease Fibrinogen alpha, Lysozyme
Familial British dementia FBDP
Familial Danish dementia FDDP
Diffuse lewy body disease, Parkinson’s disease α-synuclein
Fronto-temporal dementia Tau
Amyotropic lateral sclerosis Superoxide dismutase-1
Triplet repeat diseases: (Huntinghton’s, Spinocerebellar ataxias Polyglutamine tracts (Huntingtin)
Spinal and bulbar muscural atropy Androgen receptor
Spinocerebellar ataxias Ataxins
Spinocerebellar ataxia 17 TATA box-binding protein
Table 1. Diseases of protein misfolding: amyloidoses and non-amyloidoses (reviewed in [1])
Both the amyloid forming proteins involved in certain conformational disease and model
proteins are used (Table 2). Stefin B is a model protein for studying amyloid fibril formation.
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SH3 domain p 85 phosphatidylinositol 3-kinase Fibronectin type III phosphoglycenite linase acylphosphatase
HypF N-terminal domain (E. coli) Amphoterin (human)
Apomyoglobin (equine) Apocytochrome c
Endostatin (human) Met aminopeptidase
Stefin B (human) ADA2H
Fibroblast growth factor (N. viridescens) Apolipoprotein CII
VI domain (murine) B1 domain of IgG binding protein
Curlin CgsA subunit Monellin
Serpins
Table 2. Nondisease related amyloid forming proteins/peptides – model proteins (reviewed in [1]) serpins leads to
diseases when there are mutations inducing aggregation or change of conformation (e.g. see serpinopathies and the
Conformational dementias by David A. Lomas and Robin W. Carrell [2].
2. Human stefin B
Stefins are endogenous cysteine protease inhibitors [3], which are ubiquitously expressed in
human tissues [4]. They are specific for the papain-family of cysteine proteases and classified
as the IH clan in the MEROPS scheme [5]. They are mainly intracellular inhibitors, although
have also been found outside the cell in body fluids [6]. They do not have a signal peptide, and
they bear a cystatin motif QXVXG, which is the main site involved in binding to target enzymes.
Human stefin B (also termed cystatin B) possesses 98 amino acid residues (Mr= 11 kDa) and
no carbohydrate groups or disulphide bridges [7], although it contains one free cysteine [8]. It
is an intracellular protein, which tightly and reversibly binds to papain-like cysteine proteases.
We will simply call it stefin B from now on.
Stefin B main function is protection against inappropriate proteolysis of lysosomal cysteine
proteases [9]. It is an inhibitor of cathepsins B, L, H and S [7, 10, 11]. However, it exerts some
additional functions. It was found to interact with five known non-protease proteins (neuro‐
filament light chain (NFL), brain β-spectrin, RACK-1, human myotubularin related protein 8
(Mtrp) and human T-cell activation protein (Tcrp)) [12]. NFL and β-spectrin are specific to the
nervous system. Stefin B (cystatin B) knock-out mice show neurological disorder (loss of the
cerebellar granule cells, because of apoptotic bodies, chromatin condensation and some other
changes). This suggests that stefin B has an essential anti apoptotic role in the cerebellum [12].
Stefin B is overexpressed in patients with hepatocellular carcinoma and is therefore in
combination with some other proteins used as a marker for this disease (it is elevated in the
Structure and Function of Stefin B Oligomers – Important Role in Amyloidogenesis
http://dx.doi.org/10.5772/57570
297
serum already at the early stage of the disease development and therefore easy to detect) [13].
In different types of cancer (human colorectal cancer [14], gastric cancer [15], esophageal
carcinoma [16], prostatic adenocarcinoma [17], bladder cancer [18]…) both lower expression
level and higher activity due to higher expression level have been detected.
Stefin B is localized both in the cytosol and in the nucleus [19, 20]. It is expressed in neurons
and glial cells in the brain, but with slightly different localizations; in neurons it localizes to
the nucleus while in astrocytes it is localized in the nucleus and in the cytoplasm [21]. It inhibits
cathepsin L in the nucleus, whose substrates are transcription factors. Interaction with
nucleosome – histones H2A.Z, H2B and H3, and cathepsin L in the nucleus has also been
reported [19]. Therefore, it likely regulates transcription. Furthermore, stefin B was reported
to regulate cell cycle progression into the S phase – entry into the S phase is delayed [19].
Increased expression of stefin B in the nucleus of T98G astrocytoma cells delays caspase-3 and
caspase-7 activation and this delay is independent of cathepsin inhibition [22].
Stefin B plays an important role in the immune system. It upregulates the release of nitric oxide
from interferon-γ-activated macrophages [23]. The protein is involved in innate immune
response to bacterial challenge of the leech Theromyzon tessulatum [24]. It has an essential role
in protection of the central nervous system from apoptosis [25] and from oxidative stress [26].
Increased level of stefin B was found in the senile plaques of Alzheimer’s and Parkinson’s
diseases and in samples of patients suffering from senile dementia [27].
Stefin B functions are summarized in Table 3.
Loss of functions because of alterations in the cystatin B gene (dodecameric repeat expansions
in the promoter region or point mutations in the coding gene) is the cause of progressive
myoclonus epilepsy of type 1 also known as Unverricht-Lundborg disease (EPM1) [25, 28].
EPM1 mutans are polymeric and aggregate prone in vivo [29]. In vitro and ex vivo G4R, R68X,
[30, 31], G50E and Q71P [32, 33] have been studied. Only G4R mutant folds like the wild type
protein [31], all others lack tertiary structure and are partially unfolded [31, 33]. G4R and R68X
also form amyloid fibrils [31]. Both G50E and Q71P mutants are more susceptible to cleavages
by proteases, because of the partially unfolded structure [33], which likely contributes to loss
of function in cells. Stefin B deficiency triggers neurodegeneration by impaired redox homeo‐
stasis [26]. G4R and R68X do not have any inhibitory activity, while G50E and Q71P are much
less active than the wild type protein [32]. All three missense mutants, except for G4R form
rather large but diffuse aggregates in cells when over-expressed, while G4R forms small
aggregates similar to those of the wild type protein [32].
Cystatin C, a secreted and extracellular protein, is another cysteine protease inhibitor and
mutations in its gene are the cause of hereditary cerebral amyloid angiopathy [34]. Human
cystatin C is a risk factor for late onset Alzheimer’s disease. The protein co-deposits with
amyloid β peptide (Aβ peptide) amyloid plaques in patients with Alzheimer’s disease [35].
Moreover, cystatin C binds to both the whole amyloid precursor protein (APP) and to Aβ
peptide and it inhibits Aβ peptide amyloid fibril formation in vitro [36].
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Stefin B functions
inhibition of cathepsins B, L, H and S [7, 10, 11];
interaction with five non protease proteins: neurofilament light chain (NFL), brain β-spectrin, RACK-1, human
myotubularin related protein 8 (Mtrp) and human T-cell activation protein (Tcrp) (NFL and β-spectrin are specific
to the nervous system) – essential anti apoptotic role in the cerebellum [12];
involved in immune-response to bacterial challenge of the leech Theromyzon tessulatum [24];
increased level in the senile plaques of Alzheimer’s and Parkinson’s and of patients suffering from senile
dementia [27];
essential role in some of the neurons in the central nervous system, protecting the cells against apoptosis [25];
protects thymocytes against cell death [37];
cell specific expression [21];
inhibits Aβ peptide amyloid fibril formation in oligomer specific manner [38];
positive/negative progression of cancer [13-18];
upregulation of nitric oxide release from interferon-γ-activated macrophages [23];
found mainly in the nucleus of proliferating cells and both in the nucleus and cytoplasm of differentiated cells;
regulates cell cycle [19];
increased expression in the nucleus delays caspase activation [22];
protecting cells from oxidative stress [26].
Table 3. Stefin B has many different functions.
3. Stefin B oligomers in vitro and in cells
Stefin B can adopt different oligomeric states in vitro and in cells. On the size-exclusion
chromatography (SEC) the wild type protein elutes as a set of well-defined oligomers apart
from monomers, dimers, tetramers and even higher oligomers (Figure 1) [39]. Y31 isoform is
predominantly dimeric [31], while Y31 P79S mutant is tetrameric [40]. All oligomers can be
isolated as separate peaks by SEC and stay stable for weeks at pH 7.0 and 4 °C [38].
SEC results have been confirmed up to decamers by electrospray-ionization mass spectrometry
(ESI-MS) [41]. In cells stefin B is present both in monomeric and oligomeric forms. Oligomers
size ranges between 10 and 250 kDa. The higher oligomeric species are resistant to 1% SDS and
8 M urea and partially resistant to reducing agents (DTT treatment). The low molecular species
comprise monomers, dimers, trimers and pentamers. Stefin B polymers in vivo seem to grow
by monomer addition and not by domain-swapped dimer addition. The protein binds to many
different proteins of various sizes [29]. Already the endogenous stefin B forms small punctate
aggregates in cells and after overexpression the aggregates amount increases [30].
Oligomers have been observed for many other proteins, especially the amyloidogenic ones.
Oligomeric species appear in the lag phase of the reaction and are usually more stable under
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non-amyloidogenic conditions. Size and morphology of those oligomers can be determined
by SEC, mass spectrometry, dynamic light scattering and analytical ultracentrifugation. Some
examples are given below.
Serpins are serine protease inhibitors also used as a model for studies of amyloid fibril
formation. They have key regulatory functions in the inflammatory, complement, coagulation
and fibrinolytic cascades [2]. The mechanism of their fibril formation is known in crystallo‐
graphic details [42, 43]. They form amyloid fibrils through domain-swapping [44]. Serpins
preferably oligomerize than interact with other proteins [45]. They form both smaller oligom‐
ers and condensed longer polymers [46]. Monomers of some serpins are meta-stable with the
rate limiting step representing the transition to the dimer. Once dimers are formed, they can
connect to each other to form tetramers or recruit monomers to form trimers and also much
longer oligomers [47].
Aβ peptide forms a set of oligomers from monomer to hexadecamer; all even and odd
numbered oligomers have been detected by ESI MS [48]. Also for many other amylod forming
proteins the whole set of oligomeric species has been observed (insulin [49], β2-microglobulin
[50, 51], SH3 domain [52]…).
Figure 1. Elution profile of stefin B wild type protein (S3E31 form) at pH 7.0 from SEC. The whole sample (top trace)
and separated oligomers as indicated, are shown.
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4. Inhibitory activity of stefin B oligomers
For a long time it has been thought that monomer is the only active form of stefin B. All other
oligomeric forms would serve as a reservoir of monomers or possess additional functions.
Now we have shown that all types of oligomers are active against cysteine protease papain
(Figure 2). Dimers which are presumably domain-swapped (discussed in the structural
characterization part) show the lowest activity in the enzyme to inhibitor 1:2 ratio. They, as
well as other oligomers – tetramers and higher, are fully active in the enzyme to inhibitor 1:4
ratio (Fig. 2). SEC-isolated oligomers are all >95% pure and the amount of monomer present
in other oligomers samples has been tested to show that the inhibitory effect is not due to
monomer contamination. Higher oligomers are a mixture of various oligomers, starting from
hexamers. The highest peak represents octamers, which are the prevalent species and therefore
we propose that the average size of the higher oligomer is an octamer (this was used for
determining the molar ratio). The sample of the higher oligomers contains a small amount of
all other oligomers and we suspect that some inhibitory effect could be due to this contami‐
nation, but possibly not the whole effect. The results are in agreement with the detection of
different oligomers in cells [29] and explain that all detected species could retain inhibitory
function.
Figure 2. Different stefin B oligomers all exert inhibitory activity against the cysteine protease papain. To evaluate the
inhibitory activity of stefin B, BANA test was performed [53]. Stefin B monomers, dimers, tetramers and oligomers
were prepared in eight different molar ratios [E]:[I]– 1:45, 1:22, 1:11, 1:4, 1:2, 1:0.2. Higher absorbance means lower
inhibitory activity. The average oligomeric state (the highest peak from SEC) in the sample of higher oligomers are the
octamers.
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5. Structural characterization of different oligomeric states of stefin B
Crystal or solution structure of stefin B monomer and oligomers have been so far characterized
from monomer in complex with the target enzyme [54], dimer under amyloid forming
conditions [55], tetramer [40] to model of amyloid fibrils [56]. Domain-swapped dimer of stefin
A has also been determined by heteronuclear NMR [57].
Stefin B was first crystallized in complex with the cysteine protease papain (Figure 3A) [54].
The structure of the monomeric stefin B consists of a five stranded β-sheet wrapped around a
five turn α-helix and with an additional carboxy terminal strand running along the convex
side of the β-sheet. This type of the tertiary structure is conserved throughout the cystatin
family (Fig. 3A)
High resolution structure of stefin B dimer was determined by heteronuclear NMR [55].
Furthermore, changes within the dimer under amyloid forming conditions were observed and
flexible residues were defined. Even under amyloid forming conditions the structure remains
largely folded, the main differences are in the flexible loops regions. Prolines on positions 74
and 79 play an important role in the orientations of the loop between strands 4 and 5 (the same
loop is involved in “hand-shaking” in the tetramer formation). Four different dimer states have
been observed in solution.
When the proline at position 79 was mutated into serine, the tetrameric form of the protein
became favourable [40]. This tetramer has been crystallized and its structure determined
(Figure 3B) [40]. The tetramer consists of two domain-swapped dimers connected with the so-
called “hand-shaking” mechanism to each other. Hand-shaking occurs along with trans to cis
isomerization of the proline at position 74. This proline is conserved throughout the cystatin
family. Both domains preserve the fold of the monomer (the same as observed in the complex
with papain); each domain is composed of the N-terminal part from one chain (strand 1, the
α-helix and strand 2) and C-terminal part from the other chain (strands 3, 4 and 5), between
both domains there is a linker region (two peptides, belonging each to one chain).
The structured core of human stefin B amyloid fibrils has been determined (Figure 3C) [56].
Based on the H/D exchange rates the structure could be divided onto protected region (inside
the fibril core) and unprotected region (striking out of the fibril). Strands 2, 3, 4 and 5 are
protected, while strand 1, α-helix and loops between strands 3 and 4 and 4 and 5 are unpro‐
tected. The loop between strands 2 and 3 is the same as the one involved in the domain-
swapping mechanism. The fibril core would therefore be made of domain-swapped dimers
but with the loop between strands 4 and 5 in position of a tetramer.
6. Initial oligomers on the way to fibril formation
That stefin B forms amyloid fibrils in vitro under relatively mild conditions was first shown in
2002 [58] and various solution conditions were probed, fibrils and protofibrils were imaged
by AFM and TEM [59]. The fibril formation of stefin B was compared to that of stefin A, a much
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more stable homologue [60], to proline mutants [61], EPM1 mutants [62] and to chimeras
between stefins A and B [63].
A model for the mechanism of stefin B amyloid fibril formation has been proposed based on
temperature and concentration dependence of the kinetics [64]. Following changes during the
lag phase of the reaction by SEC and ESI MS we were able to improve the model of amyloid
fibril formation (Figure 4), further explaining the role of various off-pathway oligomers [41].
Dimers seem to be the building block from which fibril formation starts and the fibrils grow
[56]. When the process was started from any kind of oligomers, these transformed into dimers
[41]. NMR studies have shown that there are actually four types of dimers observed in the lag
phase under amyloid forming conditions [55].
Figure 3. Stefin B structure. (A) stefin B monomer (PDB 1stf) [54], (B) stefin B tetramer (PDB 2oct) [40], (C) secondary
structure representation of stefin B fibril [56]
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Figure 4. The proposed mechanism for amyloid fibril formation by stefin B [41]. Non-toxic species are coloured green,
toxic are coloured red and potentially toxic are coloured orange.
7. Oligomeric state related toxicity
Stefin B higher oligomers are equally toxic to cells as the molten globule state (mutant P74S
Y31) [39]. Higher oligomers still have native like CD spectra and increased ANS binding, which
would mean that they are properly folded. The toxicity seems to correlate with the ANS
binding (ANS binding is indicator of exposed hydrophobic patches in the protein structure)
[39]. MTS test has shown that isolated dimers and tetramers are not toxic (Figure 5A), while
higher oligomers show some toxicity to neuroblastoma cells (SH-SY5Y). In accordance, low
ordered oligomers, monomers, dimers and tetramers do not increase caspase-3-like activity
(Figure 5B) [39]. All those results correlate with insertion into lipid membranes, where toxic
species insert more effectively than not toxic. Monomers do not get internalized into the
cytoplasm when added to the cell medium, while higher oligomers do [39].
Confirming the above results, in another study [65] it was demonstrated that a mutated P74S
Y31 form of stefin B, which is molten globule at neutral pH and prefibrillar aggregates at pH
3, which are also in the molten globule conformation, are most toxic.
A growing body of evidence shows that the soluble oligomers formed during amyloid fibril
formation exert toxicity and likely cause neurodegeneration [66]. Small soluble oligomers are
the cause of synaptic disfunction, whereas large and insoluble aggregates are likely the
reservoir of those toxic species [66]. In the case of Aβ peptide a significant correlation has been
found between the levels of soluble oligomers and the degree of synaptic alteration, neurode‐
generation and cognitive decline, while the correlation between insoluble deposits and those
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symptoms has not been demonstrated [67]. Non fibrilar dimers or oligomers of α-synuclein
could play a major role in Parkinson’s disease progression [68]. In accordance with a generic
process of amyloid type of protein aggregation, not only oligomers of amyloidogenic proteins
related to amyloid diseases exert toxicity, also HypF-N from E. coli, SH3 domain of PI3 kinase
and some other proteins form oligomers that are toxic to fibroblasts and neurons, whereas
amyloid fibrils of the same proteins show only low toxicity [69, 70].
Conformation dependent antibodies distinguish between soluble oligomers [71-73] and
amyloid fibrils [74, 75]. Many of those antibodies recognize the generic epitopes regardless of
the amino acid sequence and this suggests that different proteins form structurally similar
oligomers and fibrils. It was shown that the antibody recognizing Aβ peptide fibrils, recognize
also fibrils of transthyretin, islet amyloid polypeptide, β2-microglobulin and polyglutamine
and that the same antibody does not recognize soluble oligomers of those proteins nor the
native forms [75]. Antibodies recognizing soluble oligomers also inhibit their toxicity which
suggests that soluble oligomers do not share only structural properties but also the mechanism
of toxicity [72].
Figure 5. Viability of cells exposed to prefibrillar aggregates and oligomers of stefin B. (A) MTS test-viability of the
SHSY5Y cells was measured after exposure for 16 hours to serum free medium, which contained prefibrillar oligomers
of stefin B – StBpH3, StBpH5, StBpH3F (filtered), and separated dimers, tetramers and higher-order oligomers of stefin
B at pH 7 – StBpH7; each at a final concentration of 44 µM. As a control for the effect of a non-toxic protein, cells were
exposed for the corresponding length of time to 44 µM of soluble stefin A prepared at pH 5 (StApH5). All the results
are relative to the cells alone, with no added substance or protein in the medium. (B) DEVD-ase activity after exposing
SHSY5Y cells to prefibrillar aggregates. 200 µl of concentrated StBpH3 aggregates were added to 800 µL of cell medi‐
um to a final concentration of 44 µM (final pH was checked to be neutral). The cells were treated for four hours with
0.5 µM staurosporine (STS). Statistics-as described [39].
Both oligomers and amyloid fibrils are harmful for the cells; oligomers present mostly the toxic
effect, while amyloid fibrils present steric obstacles.
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• the disruption of the tissue architecture and functions promoted by the invasion of the extracellular space of organ
by amyloid [76, 77]
• the destabilization of intracellular and extracellular membranes by oligomers [78, 79]
• the apoptotic cell death and receptor-mediated toxicity triggered by the oligomer interaction with various neuronal
receptors [80]
• the oligomer-mediated impairment of the P/Q-type calcium currents [81]
• the impaired maturation of autophagosomes to lysosome mediated by the oligomer accumulation [82]
• the dysfunction of autophagy, a lysosomal pathway for degrading organelles and proteins [83]
• the oxidative damage-induced disruption of the cell viability promoted by the incorporation of redox metals into
amyloid fibrils and subsequent generation of reactive oxygen species [84-88]
• the general disorganization of cellular protein homeostasis associated with the exhaustion of the cell defence
mechanisms, such as chaperone system [89, 90]
• proteasome inhibition [91]
• the loss of crucial protein functions and/or gain of toxic functions
Table 4. Cellular degeneration after protein oligomerization/deposition (summarized in [92])
8. Oligomeric state related membrane interactions
Amyloid forming proteins interact with biological membranes and even form pores, which
are similar to those formed by the pore-forming proteins [1, 93]. Interactions between stefin B
and membranes have been extensively studied [65, 94, 95]. Three different proteins have been
studied: wt protein, Y31 isoform and G4R mutant (mutant involved in EPM1 disease). Also
some comparisons have been made between native and prefibrillar states of the protein
(prepared with incubation at pH 3.3 or 4.8) (Figure 6) [94]. Prefibrillar oligomers may be
organized in such a way that they are more amphipatic than the native protein and therefore
acquire a higher surface-seeking potential. All forms of the protein insert into acidic lipid
membranes, cause permeabilization of unilamelar vesicles and destabilize the membranes [94,
95]. Nevertheless there are some significant differences between them concerning pore
formation. The mutant G4R does not form pores, but breaks the membrane very fast (in a few
minutes), while both the wt protein and Y31 isoform form pores; wt pores are cation selective
(and may not be deleterious for the cell) and Y31 pores are anion selective [95]. Wt sample was
separated into different oligomers apart from monomers, into dimers, tetramers and higher
oligomers. Monomers, dimers and tetramers insert into lipid membranes with approximately
the same critical pressure, while the higher oligomers (average size is around octamers) insert
more effectively [65].
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The exact mechanism of amyloid induced toxicity is yet controversial; nevertheless the pore
formation into plasma or mitochondrial membrane is now the leading theory of pathogenesis.
Aβ peptide needs anionic phospholipids for binding and insertion into membranes [96-101].
Monomeric form does not interact with membranes. Amylin (islet amyloid polypeptide)
readily forms pores into planar lipid bilayer, preferring negatively charged lipids and
furthermore the channel activity is inversely proportional to the amount of negative surface
charge in the membrane [102]. Native form of prion protein does not form pores, while the
mutant prion protein forms irreversible pores in the lipid bilayer. They claim that the pore
formation is the main cause of the prion disease [103]. α-synuclein, a natively unfolded protein,
also forms pores into lipid membranes but in contrast to others described it is not known how
does the oligomeric form increase membrane permeability without forming discrete channels
[104]. In the literature we can find contradictory results what effects amyloid proteins exert on
membranes. For the same proteins we can find reports that they affect membranes by a non-
channel mechanism and other reports that they affect membranes by the formation of ion
channels. Two mechanisms of pore formation into membranes by the amyloid forming
proteins are summarized in Table 5.
Figure 6. Binding of stefin B variants to liposomes as measured by SPR. (A) Binding to PC LUV. A comparison of bind‐
ing of 70 µM stefin variants to PC LUV immobilized on the surface of a L1 sensor chip. (B–D) A comparison of the bind‐
ing of prefibrillar form of stefin variants to PG LUV. The concentration of the protein was 10, 20, 40, 50, 60 and 70 µM
(curves from the bottom to the top) in each case. The thick gray line represents binding of native stefin variants at
70µM. (B) StB-wt; (C) StBY31; (D) G4R [95].
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Membrane poration followed by nonspecific membrane
leakage – increased conductivity of the membranes by a
non-channel mechanism
Specific ion transport through ion channel followed by
destabilized ionic homeostasis
Aβ40 peptide [105] Aβ40 peptide [106, 107]
Aβ42 peptide [105] Aβ42 peptide [108]
α-synuclein [105] Aβ22-35 peptide [109]
IAPP or amylin [105, 110] α-synuclein [111]
Polyglutamine [105] IAPP or amylin [112]
Prion (106-126) H1 [105] stefin B [95]
SOD1 [113]
Table 5. The mechanisms underlying globular peptides induced cell dysfunction
9. Copper binding to stefin B and its inhibition of amyloid fibril formation
Divalent metal ions (Cu (II), Zn (II), Fe (II)) are often observed to colocalize with amyloid
plaques in vivo in much higher concentrations than usually present in the normal environment.
This has led to the hypothesis that this metal ions bind to mature fibrils and influence the fibril
formation reaction [114].
Indeed it was proven that human stefin B is a copper binding protein [114]. It shows a
picomolar affinity to copper at pH 7 and a nanomolar affinity at pH 5. Both the wild type
protein and the Y31 isoform bind copper, while the Y31 P79S, which is tetrameric, does not.
Monomers and dimers are able to bind copper, while other oligomers are not. Copper binding
does not change the conformation of the protein; however it inhibits amyloid fibril formation
(Figure 8). Of note it does not prevent aggregation to prefibrillar oligomers, which can be even
more toxic to cells. The protein binds two Cu2+ ions. Copper binding promotes protein
dimerization at neutral pH, while at acidic pH protein undergoes dimerization, already
without added copper [114].
Later-on, NMR was used to detect the three possible copper binding sites of stefin B. The first
is in the α-helix facing away from the β-sheets together with the loop between strands 4 and
5. The second potential binding site is the C-terminal together with the loop between strands
3 and 4 (this binding site is more likely in the dimeric form of the protein). The third binding
site is in the dimer only and is the loop between strands 2 and 3, which is the stretched loop
in the domain-swapped dimer together with the few residues at the N-terminal [55].
It was confirmed that copper affects the stefin B fibril formation. In more details, it slows down
the elongation phase. It was also shown that the presence of copper destabilizes the protein
structure and therefore it was concluded that it preferably binds to the slightly unfolded state
of the protein. The final fibril morphology does not differ if copper ions are present or not [55].
Metal ions have different effect on amyloid forming proteins. They can speed up the fibril
formation, reduce the lag phase, retard the fibrillization or even stop the process completely
[115-117].
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Binding of metal ions to prion protein increases proteolysis resistance and structural changes
which might play an important role in the conversion process [118].
SOD1 aggregation is enhanced and modulated by Ca2+ ions; at physiological pH Ca2+induces
conformational changes that increase β-sheet content, they can also divert the aggregation from
amyloid fibrils to amorphous aggregates [119]. Cu2+ and Zn2+ accelerate deposition of Aβ40
peptide and Aβ42 peptide, which results in the amorphous aggregates [120, 121]. Fe3+ induces
the deposition of fibrillar amyloid plaques of Aβ40 peptide and Aβ42 peptide [120]. Prion
protein can directly influence neuronal zinc concentrations [122]. In prion plaques there was
found a significant disregulation of copper and manganese, copper was depleted and man‐
ganese was enriched [123]. Fe3+ and Al3+ enhance both formation of mixed oligomers and
recruitment of α-synuclein in pre-formed tau oligomers [124]. Copper and selenium inhibit
amylin fibril formation, while aluminium and manganese promote it [125]. Copper amylin
complex has an anti-aggregating and anti-apoptotic properties, quenching the metal catalysed
ROS [126]. Zinc also inhibits amylin fibril formation, furthermore, it favours the formation of
amylin hexamers and inhibits the formation of dimers [127].
10. Interaction between oligomers of stefin B and Aβ peptide in vitro and
in cells-“amateur chaperones”
“Professional chaperones” (heat shock protein family) prevent protein misfolding and
subsequent protein aggregation. “Amateur chaperones” bind amyloidogenic proteins and
may affect their aggregation process. Both types of chaperones colocalize with pathological
lesions of Alzheimer’s disease, may be involved in Aβ peptide conformational changes,
clearance of Aβ peptide from the brain. Both types of chaperones may be involved in the
Figure 7. Inhibition of fibrillation of stefin B by Cu2+ as probed by ThT fluorescence. Final protein concentration was in
all cases 45 µM and final concentration of Cu2+ 46 µM, leading to 1 : 1 of protein to Cu2+ ratio. (A) Stefin B wildtype
(E31 isoform) at pH 5, 40 °C, 0 and 50 µM Cu2+ in the buffer. (B) Stefin B wildtype (E31 isoform) at pH 5, 10% TFE, 25
°C, 0 and 50 µM Cu2+ in the buffer [114].
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aggregation, accumulation, persistence and clearance of Aβ peptide and may therefore serve
as a potential targets for medical treatment of those patients [128].
Aβ peptides are produced by proteolytic cleavage of the amyloid precursor protein (APP) by
α-secretase, β-secretase and γ-secretase. Cathepsin B, which can be inhibited by stefin B, is
likely contributor to β-secretase activity [129]. Cysteine protease inhibitors reduce both Aβ
peptide level in the brain and β-secretase activity in vivo [129]. Stefin B has an effect on
production of Aβ peptides and furthermore it also inhibits Aβ peptide fibril formation [38].
Two isoforms of stefin B (Y31 and wt E31) have been studied. Y31 isoform is predominantly a
dimer [31] while the wild type protein exist as mixture of monomers, dimer, tetramers and
even higher oligomers [39]. ThT fluorescence and transmission electron microscopy (TEM)
have shown that Y31 isoform completely inhibits Aβ peptide fibril formation (Figure 9I). The
direct interaction between those two proteins has also been shown by SPR measurements,
where concentration dependent interaction has been reported and by ESI MS where the
complex between dimer stB and monomer Aβ peptide has been detected (Figure 9II) [38].
Furthermore, isolated oligomers of the wild type protein have been studied and it was shown
that only the tetramer inhibits Aβ peptide fibril formation and that the higher oligomers show
only a weak inhibition. Stefin B also colocalizes with the Aβ peptide aggregates in cells (shown
by confocal microscopy) and with the C-terminal fragment of APP (comprising Aβ peptide
sequence) (shown by immunoprecipitation).
Molecule/protein Type of interaction
stefin B Inhibits Aβ peptide fibril formation, interaction in vitro and in cells [38].
laminin Inhibits Aβ peptide fibril formation, induce depolymerisation of preformed fibrils [130].
polyphenols Inhibits Aβ peptide fibril formation [131].
heme Prevents Aβ peptide aggregation [132].
GroEL Prevents Aβ peptide aggregation [133].
apolipoprotein E Slows down the oligomerization of Aβ peptide [134].
myelin basic protein Inhibitor of Aβ peptide fibrilar assembly [135].
cystatin C Concentration dependent inhibition of Aβ peptide fibril formation [36].
ferulic acid Inhibits Aβ peptide oligomer formation from monomers and at the same time accelerates fibrilformation from already formed oligomers [136].
S14G humanin Inhibits aggregation into fibrils and disaggregates preformed fibrils, reduces cytotoxicity effectof Aβ peptide [137].
albumin Increases the lag phase and decreases the total amount of fibrils [138]
crocetin Inhibits Aβ peptide fibril formation, destabilizes preformed fibrils, stabilize Aβ peptideoligomers and prevents their conversion into fibril [139].
Table 6. Molecules interacting with Aβ peptide
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Figure 8. (I) Inhibition of Aβ peptide fibril formation by stefin B measured by ThT fluorescence and (II) the detection of
the complex by ESI MS. (I) The Aβ peptide concentration was 17 µM throughout, pH 7.3, 40 °C. (I, A), Aβ peptide
alone, 1:1 molar ratio of Aβ to Y31 stefin B (complete inhibition) and 1:1 molar ratio of Aβ to E31 stefin B. (I, B), Aβ
peptide alone, and 1:1 molar ratios to E31 stefin B monomers, dimers, tetramers, and higher oligomers. The protein
concentrations of stefin B were 17 µM. (II) Complex detected by ESI-MS. (II, A) ESI-MS spectra of Aβ(1– 40) peptide, (II,
C) stefin B dimer (Y31 variant) and (II, B) their mixtures were recorded: (II, A), 2 µM Aβ(1– 40) peptide; (II, B), a mixture
of 2 µM Aβ peptide and 2 µM stefin B; and (II, C), 2 µM stefin B. Peaks corresponding to the Aβ peptide-stefin B com‐
plex are denoted with an asterisk and numbers above the peaks denote charge state of the ions [38].
In order to show if binding between domain-swapped dimers and Aβ peptide is a generic
property, other cystatins have been used. It was shown that only cystatin C dimers inhibit Aβ
peptide fibril formation (30% inhibition) while stefin A dimers exhibited no such effect [140].
Several molecules interacting with Aβ peptide have been reported by now (Table 6).
11. Conclusions and perspectives
Stefin B has been so far found as a good model system for studying amyloid fibril formation.
It exhibits nearly all features shared with other amyloid forming proteins: it forms mature
fibrils under mildly acidic conditions or even at neutral pH at somewhat higher temperature,
forms membrane pores and therefore promotes membrane leaking, binds copper ions and its’
oligomers are toxic. It is not a model protein only, but also could be termed an “amateur
chaperone” affecting Aβ peptide fibril formation both in vitro and in vivo [38].
We are trying to extend our in vitro knowledge to cell cultures to contribute even more to the
understanding of conformational disease. It is hoped that new knowledge of protein oligo‐
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merization and aggregation on the molecular and cellular levels will contribute to the devel‐
opment of new therapeutic strategies for patients with various conformational diseases,
including the neurodegenerative ones.
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